Background: CALHM1 controls cytosolic Ca2+ permeability and cytosolic Ca2+ concentration. It controls amyloid precursor protein (APP) proteolysis and aggregated amyloid-beta (Abeta) peptides levels in a Ca2+ dependent manner. However, no association between CALHM1 and AlzheimerÕs risk is unclear. Member of the FAM26 family of proteins. CALHM1 is predominantly expressed in the adult brain. It has also been detected in retinoic acid-differentiated SH-SY5Y cells. Also colocalizes with HSPA5 at the endoplasmic reticulum.
Positive Control: Human hepatocellular carcinoma.
Immunogen: Synthetic peptide derived from human CALHM1 protein.
Purification Method: Ammonium Sulfate Precipitation.
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide.
References: 1. Dreses-Werringloer, U., et la. A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Ab Levels, and Alzheimer’s Disease Risk. Cell 2008, 133, 1149-1161
2. Bertram, L., et al. 'No association between CALHM1 and Alzheimer’s disease risk.' Cell 2008, 135(6), 993-994.
3. Cui, P.J., et al. 'CALHM1 P86L polymorphism is a risk for Alzheimer’s Disease in the Chinese population.' J. Alzheimers Dis. 2009, Epub ahead of.
UniProt: Q8IU99.
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
